Petrolatum, White
drugOn this page
Also known as Petrolatumwhitewhite component of vusionWhite petrolatumWhite petrolatum component of vusion
Summary
Petrolatum, White (CHEMBL1201719) is an approved unknown; indicated across 3 conditions including severe acute respiratory syndrome and skin disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201719 |
| Name | Petrolatum, White |
| Type | Unknown |
| Max phase | 4 |
Also known as: Petrolatum, white, white component of vusion, White petrolatum, White petrolatum component of vusion, PETROLATUM, WHITE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| skin disorder | 1 | MONDO:0005093 | EFO:0000701 |
| psoriasis | 1 | MONDO:0005083 | EFO:1001494 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 3 |
| PHASE4 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01143714 | PHASE4 | COMPLETED | A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers |
| NCT01253135 | PHASE1 | COMPLETED | Study to Determine if Fibrin Affects the Ability of a Wound to Heal |
| NCT03502434 | PHASE1 | COMPLETED | A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers |
| NCT03916250 | PHASE1 | COMPLETED | Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants |
| NCT04851522 | EARLY_PHASE1 | WITHDRAWN | Dilute Bleach Compresses for Radiation Dermatitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.